## **Multiple Sclerosis** enrollment form



Date needed Medication start da			late	Ship to: □	Patient □Physician □Oth	er:		
Patient inform	ation							
Patient name D					Phone	Alternat	e phone	
Address		I		City	State	ZIP		
Gender: ☐ Male	☐ Female	Email		Pi	imary language	Height	Weight	
Dunnauih av infe	was arkin a							
Prescriber info	ormation		State License #		NPI#	DEA #		
Prescriber name Group or hospital					City	State	ZIP	
Phone		Fax	Address	Contact person name and phone		State	ZIP	
Priorie		rdx		Contact persor	папе апа рпопе			
Insurance info	rmation: If avail	able, please fax	a copy of the pres	scription and	insurance card(s) with thi	s form (front a	nd back).	
Clinical								
Date of diagnosis		Diagnosis: G35 M	•	ancina Domitti	ng □Secondary Progressive	□ Drimary Broo	roccivo	
Number of relapse	es last year:	Other (ICD-10	=	apsing-Remittii	gsecondary Progressive		ressive	
Previous disease-modifying therapy:				Current medications:				
Allergies:			Is the patient new to therapy? ☐ Yes ☐ No					
				l l				
Prescription in								
Medication	Dose/strength		Directions				Quantity	Refill
<ul><li>☐ Aubagio</li><li>☐ Teriflunomide</li></ul>	☐ 7 mg Tablet ☐ 14 mg Tablet		☐ Take 1 tablet by 1	mouth once dail	У		☐ 30 Tablets	
	☐ 30 mcg/0.5 mL Prefilled Syringe ☐ 30 mcg/0.5 mL Pen		☐ Titration Dosing (PFS): Week 1: Inject 7.5 mcg IM					
☐ Avonex			Week 2: Inject 15 mcg IM Week 3: Inject 22.5 mcg IM Week 4: Start injecting 30 mcg IM every 7 days				☐ 1 Kit = 4 PFS ☐ 1 Kit = 4 Pens	
Avoilex								
			☐ Inject 30 mcg IM every 7 days					
			☐ Titration Dosing: Take 1 capsule by mouth 2 times daily for 7 days, then 2			ays, then 2	☐ 120 Capsules	NA
☐ Bafiertam ☐ 95 mg Capsule		capsules 2 times daily thereafter					117	
			☐ Take 2 capsules		☐ 120 Capsules			
	□ 0.3 mg Vial		☐ Titration Dosing:  Weeks 1–2: Inject 0.0625 mg (0.25 mL) SUBQ every other day					
☐ Betaseron			Weeks 3-4: Inject Weeks 5-6: Inject	□ 1 Kit = 14				
			Week 7: Start inj		Devices			
			☐ Inject 0.25 mg (1	mL) SUBQ eve	) SUBQ every other day			
☐ Copaxone			☐ Inject 20 mg SUI	☐ 1 Kit = 30 PFS				
☐ Glatopa ☐ 20 mg/mL Prefilled Syringe		☐ Inject 40 mg SU	☐ 1 Kit = 12 PFS					
☐ Glatiramer acetate	☐ 40 mg/mL Prefilled Syringe		Other:					
□ Dalfampridine □ 10 mg ER Tablet			☐ Take 1 tablet by 1	mouth 2 times d	aily approximately 12 hours ap	art	☐ 60 Tablets	
Physician sigr	nature required							_
Product subst	itution permitte	ed		Dispen	se as written			
110000130031				-				

Ancillary supplies and kits will be provided as needed for administration.

The information included in this FAX is intended for the sole use of the individual to whom it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended addressee, nor authorized to receive for the intended addressee, you are hereby notified that you may not use, copy, disclose or distribute this information. If you have received this FAX in error, please contact the sender and destroy the entire document.

□ Extavia	□ 0.3 mg Vial	☐ Titration Dosing:  Weeks 1-2: Inject 0.0625 mg (0.25 mL) SUBQ every other day  Weeks 3-4: Inject 0.125 mg (0.5 mL) SUBQ every other day  Weeks 5-6: Inject 0.1875 mg (0.75 mL) SUBQ every other day  Week 7: Start injecting 0.25 mg (1 mL) SUBQ every other day  ☐ Inject 0.25 mg (1 mL) SUBQ every other day					☐ 1 Kit = 15 devices					
□ Gilenya				itner day				☐ 30 Tablets				
Fingolimod	□ 0.5 mg Capsule	☐ Take 1 capsule by mout	☐ Take 1 capsule by mouth once daily									
☐ Kesimpta	☐ 20 mg/0.4 mL Pen	_	☐ Initial Dose: Inject 20 mg SUBQ on day 1, day 8, and day 15, followed by 20 mg once monthly starting on day 29									
		☐ Inject 20 mg SUBQ onc	□1 Pen									
	CYP2C9 Genotype *1/*1, *1/*2, and *2/*2		☐ Titration Dosing: Take 0.25 mg by mouth day 1-2, 0.5 mg day 3, 0.75mg day 4, 1.25 mg day 5, followed by 2 mg daily thereafter						NA			
	☐ Titration Pack (5-day) ☐ 2 mg Tablet	□ Take 1 tablet by mouth	onco daily		-			☐ 30 Tablets				
□ Mayzent	CYP2C9 Genotype *1/*3 or *2/*3*	-	☐ Take 1 tablet by mouth once daily ☐ Titration Dosing: Take 0.25 mg by mouth day 1-2, 0.5 mg day 3, 0.75 mg day 4,					☐ 1 Titration Kit	NA			
	☐ Titration Pack (4-day)	followed by 1 mg daily t	thereafter					= 7 Tablets				
	□ 1 mg Tablet	☐ Take 1 tablet by mouth	☐ Take 1 tablet by mouth once daily									
		Treatment course:										
		Take by mouth daily at intervals of 24 hours approximately the same time each day.  Check the box of the row corresponding to the number of tablets to prescribe in the first and second cycle.										
		First Cycle (Month 1)				I						
	□ 10 mg tablet	Weight range (kg)	Day 1	Day 2	Day 3	Day 4	Day 5	Total tablets	Refill			
		☐ 40 to < 50	1 tab	1 tab	1 tab	1 tab	-	4 (40 mg)	NA			
		□ 50 to < 60	1 tab	1 tab	1 tab	1 tab	1 tab	5 (50 mg)				
		□ 60 to < 70	2 tabs	1 tab	1 tab	1 tab	1 tab	6 (60 mg)				
		□ 70 to < 80	2 tabs	2 tabs	1 tab	1 tab	1 tab	7 (70 mg)				
		□ 80 to < 90	2 tabs	2 tabs	2 tabs	1 tab	1 tab	8 (80 mg)				
		□ 90 to < 100	2 tabs	2 tabs	2 tabs	2 tabs	1 tab	9 (90 mg)				
☐ Mavenclad		□ 100 to < 110	2 tabs	2 tabs	2 tabs	2 tabs	2 tabs	10 (100 mg)				
		□ ≥ 110	2 tabs	2 tabs	2 tabs	2 tabs	2 tabs	10 (100 mg)				
		Second Cycle (Month 2)										
		Weight range (kg)	Day 1	Day 2	Day 3	Day 4	Day 5	Total tablets	Refill			
		☐ 40 to < 50	1 tab	1 tab	1 tab	1 tab	-	4 (40 mg)				
		□ 50 to < 60	1 tab	1 tab	1 tab	1 tab	1 tab	5 (50 mg)				
		□ 60 to < 70	2 tabs	1 tab	1 tab	1 tab	1 tab	6 (60 mg)				
		☐ 70 to < 80	2 tabs	2 tabs	1 tab	1 tab	1 tab	7 (70 mg)	NA NA			
		□ 80 to < 90	2 tabs	2 tabs	1 tab	1 tab	1 tab	7 (70 mg)				
		□ 90 to < 100	2 tabs	2 tabs	2 tabs	1 tab	1 tab	8 (80 mg)				
		□ 100 to < 110	2 tabs	2 tabs	2 tabs	2 tabs	1 tab	9 (90 mg)				
		□ ≥ 110	2 tabs	2 tabs	2 tabs	2 tabs	2 tabs	10 (100 mg)				
☐ Ocrevus	□ 300 mg/10 ml. Vial	☐ Initial Dose: Infuse 300	mg IV on da	y 1, followe	d by 300 m	g IV 14 days	slater	☐ 2 Vials	NA			
□ Ocievus	□ 300 mg/10 mL Vial	☐ Maintenance Dose: Infu	se 600 mg I	V every 6 m	nonths			L Z VIGIS				
☐ Ocrevus Zunovo	☐ 920 mg and 23,000 units/ 23 mL Vial	☐ Inject 920 mg/23,000 units SUBQ every 6 months ☐ 1 Vi						□ 1 Vial				

Physician signature required					
Product substitution permitted		Dispense as written			
X	Date	X	Date		

Ancillary supplies and kits will be provided as needed for administration.

The information included in this FAX is intended for the sole use of the individual to whom it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended addressee, nor authorized to receive for the intended addressee, you are hereby notified that you may not use, copy, disclose or distribute this information. If you have received this FAX in error, please contact the sender and destroy the entire document.

C Discovide CUDO	☐ Titration Pack Prefilled Syringe☐ Titration Pack Pen	☐ Titration Dose: Inject 63 mcg SUBQ on day 1, 94 mcg on day 15, then 125 mcg on every 14 days thereafter starting on day 29	☐ 1 Titration Kit = 2 Pen/PFS	NA
☐ Plegridy SUBQ	☐ 125 mcg/0.5 mL Prefilled Syringe☐ 125 mcg/0.5 mL Pen	☐ Inject 125 mcg SUBQ every 14 days	☐ 2 Pen/PFS	
☐ Plegridy IM	☐ 125 mcg/0.5 mL Prefilled Syringe	Titration Dose: Inject 63 mcg IM on day 1, 94 mcg on day 15, then 125 mcg every 14 days thereafter starting on day 29	☐ 1 Kit = 2 PFS	
_ · · · · · · · · · · · · · · · · · · ·	_ , ,	☐ Inject 125 mcg IM every 14 days		
☐ Ponvory	☐ Titration Pack (14 Tablets)	☐ Titration Dose: Take 2 mg by mouth day 1-2, 3 mg day 3-4, 4 mg day 5-6, 5 mg day 7, 6 mg day 8, 7 mg day 9, 8 mg day 10, 9 mg day 11, and 10 mg day 12-14, followed by 20 mg once daily thereafter	☐ 1 Titration Kit = 14 Tablets	NA
	□ 20 mg Tablet	☐ Take 1 tablet by mouth once daily	☐ 30 Tablets	
☐ Titration Pack Prefilled Syringe ☐ Titration Pack Rebidose Autoinjector ☐ Rebif		☐ Titration to 22 mcg dose (PFS only):  Weeks 1-2: Inject 4.4 mcg SUBQ 3 times weekly  Weeks 3-4: Inject 11 mcg SUBQ 3 times weekly  Week 5: Start injecting 22 mcg SUBQ 3 times weekly  ☐ Titration to 44 mcg dose:  Weeks 1-2: Inject 8.8 mcg SQ 3 times weekly  Weeks 3-4: Inject 22 mcg SQ 3 times weekly  Week 5: Start injecting 44 mcg SQ 3 times weekly	□ 1 Titration Kit = six 8.8 mcg + six 22 mcg syringes or autoinjectors	NA
	☐ 22 mcg Prefilled Syringe	☐ Inject 22 mcg SUBQ 3 times weekly		
	☐ 22 mcg Rebidose Autoinjector ☐ 44 mcg Prefilled Syringe	☐ Inject 44 mcg SUBQ 3 times weekly	☐ 12 Pen/PFS	
	44 mcg Rebidose Autoinjector	☐ Other:		
☐ Tecfidera ☐ Dimethyl Fumarate	☐ Starter Kit (60 DR Capsules)	☐ Titration Dose: Take 120 mg by mouth 2 times daily for 7 days, then take 240 mg 2 times daily thereafter	☐ 1 Starter Kit	NA
	120 mg DR Capsule (dispensed in multiples of #14)	☐ Take 240 mg by mouth 2 times daily	☐ 60 Capsules	
	240 mg DR Capsule	Other:	Other	
□ Vumerity		☐ Titration Dose: Take 1 capsule by mouth 2 times daily for 7 days, then take 2 capsules 2 times daily thereafter	□ 106 Capsules	NA
	☐ 231 mg DR Capsule	☐ Take 2 capsules by mouth 2 times daily	☐ 120 Capsules	
		Other:		
☐ Zeposia	☐ Titration Pack (7-day) ☐ Titration Pack (28-day )	☐ Titration Dose: Take 0.23 mg by mouth day 1-4, 0.46 mg day 5-7, followed by 0.92 mg once daily thereafter	☐ 1 Titration Kit	NA
•	□ 0.92 mg Capsule	☐ Take 0.92 mg by mouth once daily	☐ 30 Capsules	

Physician signature required					
Product substitution permitted		Dispense as written			
X	Date	X	Date		

Ancillary supplies and kits will be provided as needed for administration.

The information included in this FAX is intended for the sole use of the individual to whom it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended addressee, nor authorized to receive for the intended addressee, you are hereby notified that you may not use, copy, disclose or distribute this information. If you have received this FAX in error, please contact the sender and destroy the entire document.